文献速递产科母胎医学

ACOG实践简报第226号:胎儿染色体异常筛查(摘要)

Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin Summary, Number 226.
PubMed 文献 · Obstet Gynecol · 2020-01-01

该实践简报概述胎儿染色体异常产前筛查,强调无单一检测在所有情况下最优,需以患者为中心进行个体化咨询。所有患者应同时获得筛查与诊断检测选项,并在充分知情后自主选择接受或拒绝。本次修订进一步明确筛查方法,并扩展了无创DNA(cfDNA)适用于所有患者(不论年龄或基线风险)的信息及咨询指导。

要点

  • 所有孕妇每次妊娠均应接受胎儿染色体异常检测选项的咨询。
  • 无单一筛查检测在所有情况下最优,需结合患者情况个体化选择。
  • 所有患者应同时获得筛查和诊断检测选项,并有权知情后接受或拒绝。

核心结论

  • 胎儿染色体异常检测应为基于充分准确信息、患者临床背景、可及资源、价值观与目标的知情选择。

研究设计与样本

  • 美国妇产科医师学会(ACOG)制定的实践简报第226号摘要,基于现有筛查检测证据进行综述并给出推荐。

主要发现

  • 各种产前筛查与诊断检测提供不同水平的信息和性能,各有相对优势与局限。
  • 没有任何一种筛查检测在所有情况下均优越。
  • 本次修订扩展了无创DNA(cfDNA)用于所有患者(不论母亲年龄或基线风险)的信息。

关键数值与推荐

  • 所有患者应同时获得筛查和诊断检测选项。
  • 所有患者有权在咨询后接受或拒绝检测。

临床怎么用

  • 产科人员每次妊娠均应就胎儿染色体异常检测选项进行咨询。
  • 咨询需讨论胎儿染色体异常风险及可用筛查与诊断检测的相对获益和局限。
  • 根据患者临床背景、资源、价值观与目标协助其知情决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. A wide variety of prenatal screening and diagnostic tests are available; each offers varying levels of information and performance, and each has relative advantages and limitations. When considering screening test characteristics, no one test is superior in all circumstances, which results in the need for nuanced, patient-centered counseling from the obstetric care professional and complex decision making by the patient. Each patient should be counseled in each pregnancy about options for testing for fetal chromosomal abnormalities. It is important that obstetric care professionals be prepared to discuss not only the risk of fetal chromosomal abnormalities but also the relative benefits and limitations of the available screening and diagnostic tests. Testing for chromosomal abnormalities should be an informed patient choice based on provision of adequate and accurate information, the patient's clinical context, accessible health care resources, values, interests, and goals. All patients should be offered both screening and diagnostic tests, and all patients have the right to accept or decline testing after counseling.The purpose of this Practice Bulletin is to provide current information regarding the available screening test options available for fetal chromosomal abnormalities and to review their benefits, performance characteristics, and limitations. For information regarding prenatal diagnostic testing for genetic disorders, refer to Practice Bulletin No. 162, Prenatal Diagnostic Testing for Genetic Disorders. For additional information regarding counseling about genetic testing and communicating test results, refer to Committee Opinion No. 693, Counseling About Genetic Testing and Communication of Genetic Test Results. For information regarding carrier screening for genetic conditions, refer to Committee Opinion No. 690, Carrier Screening in the Age of Genomic Medicine, and Committee Opinion No. 691, Carrier Screening for Genetic Conditions. This Practice Bulletin has been revised to further clarify methods of screening for fetal chromosomal abnormalities, including expanded information regarding the use of cell-free DNA in all patients regardless of maternal age or baseline risk, and to add guidance related to patient counseling.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin Summary, Number 226. Obstet Gynecol. 2020. PMID: 32976375. doi:10.1097/AOG.0000000000004107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。